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Antibodies against citrullinated fibrinogen (anti-cit-fibrinogen) have been implicated in both rheumatoid 
arthritis (RA) and cardiovascular (CV) risk in RA. The objective of this study was to examine the 
association between anti-cit-fibrinogens and coronary artery disease (CAD) outcomes. 
 
Methods 
We performed the study in an RA cohort based in a large academic institution linked with electronic 
medical record data (EMR) containing data on CAD outcomes from medical record review. Using a 
published bead assay method, we measured 10 types of anti-cit-fibrinogens. We applied a score test to 
determine the association between the anti-cit-fibrinogens as a group with CAD outcomes. Principal 
components analysis (PCA) was performed to assess whether the anti-cit-fibrinogens clustered into 
groups. Each group was then also tested for association with CAD. Sensitivity analyses were also 
performed using a published ICD9 code group for ischemic heart disease (IHD) as the outcome. 
 
Results 
We studied 1,006 RA subjects with mean age 61.0 (SD 13.0) years and 72.2% anti-CCP positive. As a 
group, anti-cit-fibrinogen was associated with CAD (p=1.1x10-4). From the PCA analysis, we observed 3 
main groups, of which only one group, containing 7 of the 10 anti-cit-fibrinogens, was significantly 
associated with CAD outcomes (p=0.015). In the sensitivity analysis, all anti-cit-fibrinogens as a group 






Anti-cit-fibrinogen antibodies as a group were associated with CAD outcomes in our RA cohort, with the 
strongest signal for association arising from a subset of the autoantibodies. 
 
Significance and Innovations  
 
• Previous studies found an association between anti-citrullinated protein antibodies (ACPA) 
directed against citrullinated fibrinogen (cit-fibrinogen) and surrogate markers of cardiovascular 
(CV) risk; this study examined the association between ACPAs and coronary artery disease (CAD) 
outcomes 
• Our study demonstrated a specific association between a subset of anti-cit-fibrinogen antibodies 
and CAD in RA, present even after adjusting for anti-CCP status 
• We provide a roadmap for a data driven approach that can be applied to study association 
between a group of biomarkers with an outcome using state-of-the-art biostatistics methods; 
the traditional approach of testing individual biomarkers with an outcome and adjusting for 





Cardiovascular disease (CVD) is a leading cause of death for patients with rheumatoid arthritis (RA)(1). 
Several studies have demonstrated that traditional CV risk calculators significantly underestimate CV risk 
in RA(2). These findings have motivated studies to examine whether biomarkers can assist 




(ACPAs) are used in the diagnosis of RA, and recent studies have identified epitope targets several 
epitope targets implicated in the disease(3-5).  A specific class of ACPAs, autoantibodies targeting 
citrullinated fibrinogen (anti-cit-fibrinogen) have been studied as potential markers for cardiovascular 
disease (CVD) in RA(6).   
 
In a previously published study, Sokolove an colleagues observed that protein lysates of atherosclerotic 
plaques from aortic specimens were enriched for citrullinated fibrinogen (cit-fibrinogen)(6).  Further, 
they found that RA patients with higher titers of anti-cit-fibrinogens also had higher atherosclerotic 
burden as measured by coronary artery calcium (CAC) scores.  These data suggested a mechanistic 
pathway whereby inflammation promoted cit-fibrinogen in atherosclerotic plaques, and thus the 
development of anti-cit-fibrinogen may be a useful marker of inflammation, atherosclerotic burden and 
CV risk in RA.  Interestingly, a subsequent study from an independent cohort using a different platform 
to measure anti-cit-fibrinogen found no association between carotid intima media thickness or CAC, and 
titers of anti-cit-fibrinogen(7). 
 
Since previous studies have only examined surrogate CV outcomes, the objective of this study was to 
examine the association between anti-cit-fibrinogen and the outcome of CAD.  Additionally, fibrinogen is 
a relatively large molecule(8) with autoantibodies targeting different portions of the citrullinated 
fibrinogen.  Thus, a secondary objective of this study was to determine whether there was specificity to 







We studied a validated RA cohort identified in the electronic medical records (EMR) of two large tertiary 
care hospitals in Boston, MA, Brigham and Women’s Hospital (BWH) and Massachusetts General 
Hospital (MGH).  Briefly, the RA cases were identified using a validated RA phenotype algorithm utilizing 
a combination of structured data, e.g. International Classification of Diseases, 9th Revision (ICD9), and 
concepts extracted from text notes, e.g. smoking status, using natural language processing (NLP). The 
positive predictive value (PPV) for RA using the algorithm was 94%(9). Discarded blood samples were 
collected using a biospecimen repository linked to anonymized EMR data and all samples were 
measured for antibodies to cyclic citrullinated peptide (anti-CCP) using a commercial kit as described in a 
previous publication(10). We studied all RA subjects with clinical data and available blood samples.  
 
CAD Outcome definition 
Subjects were classified as having CAD if they had diagnosis of CAD in the medical record with 
supporting evidence of disease through documentation of CABG, percutaneous coronary intervention 
(PCI) with stent or balloon angioplasty, positive stress test, or EKG changes consistent ischemia(11). 
Subjects with a diagnosis of CAD without supporting documentation or subjects with no mention of CAD 
were considered not to have the disease. 
 
Covariates 
Information on covariates and potential confounders were extracted from the structured EMR data 
including age, gender, self-reported race classified as white or non-white, hypertension (ICD9 401.x, 
402.x. 403.x. 404.x, 405.x) , diabetes (249.xx or 250.xx), hyperlipidemia (272.xx), and RA treatments 
(ever/never use): disease modifying anti-rheumatic drugs (DMARDs), categorized into non-biologic and 






All plasma samples were measured for anti-cit-fibrinogen using a bead-based antigen microarray as 
described previously(6). In total, we measured autoantibodies directed against 10 epitopes of cit-
fibrinogen (Table 2). Anti-CCP positivity was determined using a commercially available assay (CCP3 IgG 
ELISA, INOVA Diagnostics, San Diego, CA). 
 
Statistical analysis 
To test the association between autoantibodies as a group with the primary outcome CAD, we used the 
score test (13,14).  The use of the score test allowed us to integrate information from multiple 
correlated ACPAs at once (which individually may not be statistically significant) to determine the overall 
association of the group with the outcome.  The p-value from the score test provides a summary statistic 
for whether the biomarkers as a group are associated with the outcome.   Prior studies on ACPAs tested 
the association between individual ACPAs with an outcome.  Due to the high degree of correlation 
between the ACPAs, this approach cannot account for collinearity between ACPAs, and can further 
result in a loss of power to detect associations.  As well, each individual ACPA may have a modest effect 
size, however, as a group, the ACPAs may have a significant association with an outcome that may be 
missed with individual testing.    The score test provides information about whether there is a significant 
association between a group and an outcome.  Notably, since it is testing a group, a single effect size 
cannot be provided for the group. 
 
Since the anti-cit-fibrinogens are known to be highly correlated, we performed a Principal Component 
Analysis (PCA) to determine whether anti-cit-fibrinogen data cluster into groups based on the data. 
Briefly, PCA is a factor analysis method that highlights linear relationship between correlated variables 




of the anti-cit-fibrinogen antibody variability. PC2 explained an additional 7.7% of variability and PC3 an 
additional 3.5% of variability. Together the 3 PCs explained over 90% of the variability in anti-cit-
fibrinogen levels. From the PCA, anti-cit-fibrinogen autoantibodies clustered into three groups (Figure 
1). In addition, the same clustering was found when performing a hierarchical clustering of the data 
(data not shown). We then tested the association between each group of anti-cit fibrinogen with CAD 
outcomes using a score test in a logistic regression model, adjusting for traditional CV risk factors.  
 
We performed 3 sensitivity analyses.  First, we performed an association study using a published group 
of ICD9 codes for ischemic heart disease (IHD, ICD9 411.x or 414.x)(12), where subjects with ³1 ICD9 
code for any of those codes was defined as having IHD.  Second, we tested for association between the 
anti-cit-fibrinogen group with CAD outcome adjusting for the same covariates in the primary analysis 
with the addition of high sensitivity CRP (hsCRP) levels.  Third, we further added anti-CCP to the adjusted 
model.   
 
Statistical analyses were performed in R 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria). 
All aspects of this study were approved by the Partners Institutional Review Board (IRB). 
 
RESULTS 
We studied a total of 1006 RA patients with mean age 61.0 (SD) years, 79.0% females, and 72.2% anti-
CCP positive (Table 1). 
 
From the PCA analysis PC1 accounts for the majority of variability, 81.4%, among all anti-cit fibrinogen 
antibodies(Figure 1).  PC2 explains 7.7% and PC3 3.5% of the variability across all anti-cit fibrinogens 




three main groups (Table 2).  The anti-cit-fibrinogens (10 autoantibodies total) as a group were 
associated with a higher risk of CAD, adjusted for age, gender, race, diabetes, hypertension, 
hyperlipidemia, smoking, non-biologic DMARD, biologic DMARD and prednisone use, p=1.1x10-4 (Table 
2). When the associations were examined by subgroups, the strongest association was observed in 
Group 2 (p=0.015).  
The sensitivity analysis using ICD9 codes showed a similar association between anti-cit-fibrinogen as a 
group with IHD, as well as between Group 2 and IHD (Table 2).  We observed no association between 
anti-CCP positivity (commercial assay) with CAD, OR 1.3 (95% CI 0.7, 2.3), using the same covariates for 
adjustment.  Further we studied the subjects with hsCRP data (n=897).  The association between anti-cit 
fibrinogens and CAD remained significant adjusting for CV risk factors and hsCRP (p=2.2x10-4, for Group 
2, p=7.1x10-3).   As well, the association remained significant after adjusting the model including hsCRP 
and anti-CCP status (p=5.7x10-8; for group 2 alone, p=2.8x10-4). 
 
Discussion 
In this study, we observed a significant association between anti-cit-fibrinogens with CAD outcomes in a 
cohort of RA patients. Using a data-driven approach, we observed that the association was driven by a 
subset of autoantibodies in Group 2 (Table 2). These findings demonstrated an association between 
anti-cit-fibrinogen with the clinical outcome of CAD, adding to previous studies examining surrogate 
measures of CV risk. Moreover, this study may explain why differences have been observed with regards 
to association between anti-cit-fibrinogen and surrogate measures of CV risk(6, 7). While we detected a 
significant association between all anti-cit-fibrinogens with CAD, the signal appeared to be driven by a 




antibodies targeting specific regions of fibrinogen, an association with CAD, may not be detected.  
Additionally, an association may not be detected using individual ACPA tests. 
 
In a study by Montes et al(7) no relationship was observed between anti-cit-fibrinogen and cIMT and 
CAC scores. Their examined antibodies directed against citrullinated fibrinogen beta and not alpha. In 
the present study, we found the strongest signal to be comprised of a group of autoantibodies directed 
at citrullinated chains for both fibrinogen alpha and beta. Using the same biomarker measurement 
platform, the results of this study corroborates the previous associations observed between anti-cit 
fibrinogen and CAC scores(6). This association remained significant after adjusting for potential 
confounders including age, gender, race, and traditional CV risk factors.  The association remained 
significant after further adjustment for CRP and anti-CCP status.  Thus, the concentrations of anti-cit 
fibrinogen provided additional information in identifying which RA patients had CAD in addition to anti-
CCP.  These data also support the notion that specificity for epitope target may be important for 
identifying CAD in RA; the commercial anti-CCP assay is a mixture of cyclic antibodies against a 
proprietary set of epitope targets, whereas the anti-cit fibrinogen assays were developed using tissue 
from RA patients with characterized epitope targets.  As found in a previous study, cit-fibrinogen is 
present in atherosclerotic plaques and are recognized by ACPAs from RA patients(6). 
 
We designed this study as a “Phase 3” biomarker validation study.  Phase 3 biomarker studies focus on 
the association between previously identified candidate biomarkers, anti-cit fibrinogens with CAD 
outcome, rather than novel biomarker identification(13).  Therefore, we did not perform screening for 
other ACPAs with the CAD outcome.  However, our recently published results from a Phenome-Wide 
Association Study (PheWAS) corroborate findings from previous studies as well as our own.  This 




code data), showed a signal for association between anti-cit fibrinogens with billing codes for ischemic 
heart disease (14).  We did not observe association of other ACPAs with CV-related phenotypes. 
 
The potential mechanism or biology behind the association between cit-fibrinogen, anti-cit-fibrinogen 
and CV risk is beyond the scope of this study. However, fibrinogen is a large multi-domain glycoprotein 
and is one of the best characterized citrullinated protein targets of ACPAs in RA(8, 15). Fibrinogen is a 
known constituent of the atherosclerotic plaque for which at least a portion has been found to be 
citrullinated(16). These data suggest a potential pathway connecting citrullination of fibrinogen with 
CAD. Whether pathology occurs as a result of citrullination of fibrinogen or antibody binding of 
citrullinated fibrinogen is not known. 
 
A limitation to our study is that the samples were collected in patients who have prevalent CAD. Thus, 
this study cannot answer the question of whether anti-cit-fibrinogen is predictive of future risk.  
Notably, the association between the anti-cit fibrinogen as a group remained significant after adjusting 
for anti-CCP status.  Misclassification of RA and CAD is another potential limitation.  However, we 
believe that misclassification, particularly with CAD is more likely to attenuate the association.  
Additionally, while we adjusted for CRP, we did not have detailed information on disease activity. 
 
In summary, previous studies observed an association between anti-cit-fibrinogen antibodies with pre-
clinical CAD, and in this study with actual CAD outcomes supporting its utility as a potential marker for 
assessing CV risk in RA. While our study adjusted for traditional risk CV risk factors, future Phase 4 
biomarker development studies investigating the predictive value of these biomarkers in an 
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Table 1. Clinical characteristics of cohort (n=1006). 
Clinical characteristics CAD yes, n=93 (9.2%) CAD no, n=913 (90.8%) 
Mean age, years (SD) 71.0 (10.0) 60.0 (12.8) 
Female, n (%) 56 (60.2) 739 (80.9) 
Anti-CCP positive, n (%) 69 (74.2) 657 (72.0) 
HTN 74 (79.6) 321 (35.2) 
Hyperlipidemia 64 (68.8) 246 (26.9) 
Diabetes mellitus 29 (31.2) 84 (9.2) 
Mean hsCRP*, mg/L (SD) 13.1 (17.3) 11.4 (18.0) 
DMARD, ever use, n (%) 
Biologic DMARD, ever use, n (%) 







Methotrexate 50 (53.8) 589 (64.5) 
TNFi 
Smoking, ever, n (%) 












Table 2. The association between anti-cit-fibrinogens and CAD outcomes*. 
 
Group Anti-cit-fibrinogen Association with CAD 
p-value 





1: FA (616635) cit3 sm-cyclic 





3: FA (211-230) cit sm cyclic 
4: FB (54-72) cit1 
5: FA (41-60) cit3 cyclic 
6: FB (36-52) cit 
7: FA (27-43) cit  
8: FB (246-267) cit 




10: Fibrinogen cit 0.34 0.29 
All anti-cit-
fibrinogen 
All 10 autoantibodies above 0.00011 0.00029 
* Adjusted by age, gender, self-reported race, hypertension, diabetes mellitus, hyperlipidemia, 
nbDMARD ever use, bDMARD ever use, smoking status and prednisone ever use. 






Figure 1. Principal component analysis of anti-cit-fibrinogen antibodies demonstrating 3 main groupings 
of anti-cit-fibrinogen antibodies. (FA=fibrinogen alpha, FB= fibrinogen beta) 
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